Your selection

Innovation / 11.05.2020
US health authorities to provide USD 6 million in funding for MYELO radiation protection pill

Berlin-based MYELO Therapeutics, an affiliated company of Eckert & Ziegler Strahlen- und Medizintechnik AG, will receive USD 6 million from the National Institutes of Health (NIH) over the next three years for the further development of its radiation protection pill MYELO001. The company is one of the few European applicants to successfully compete for funds from the relatively generous US catastrophe prevention program.

The money will be used to finance further tests and proof of concept and to investigate the functional mechanism of the new orally applicable drug. If the multi-year trials are successful, MYELO has the opportunity to win valuable contracts from civil protection agencies in America and elsewhere to build up emergency stocks.

"MYELO Therapeutics is one of a series of strategic investments that Eckert & Ziegler is using to push its growth into new dimensions in the mid term," explained Dr. Andreas Eckert, CEO of the TecDAX company Eckert & Ziegler. "The Executive Board has been able to continuously increase the financial resources for this purpose over the past few years. Although it would still be years too early to make concrete statements on sales or earnings potential, the award of the contract by the American health authorities shows that Eckert & Ziegler is on the right track when it comes to selecting its financing projects".

For details of the radiation protection pill and the funding commitment of the American health authorities, see the detailed press release of MYELO Therapeutics: http://www.myelotherapeutics.com/news.html

About Eckert & Ziegler.
Eckert & Ziegler Eckert & Ziegler Strahlen- und Medizintechnik AG with more 800 employees, is one of the world's largest providers of isotope-related components for radiation therapy and nuclear medicine. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.

Overview News

News Buch Berlin

Eckert & Ziegler: Seed Implantation for Prostate Cancer Receives Reimbursement for Outpatient Care

Seed implantation for prostate cancer is now to be reimbursed as an outpatient treatment by public health insurances in Germany. This was decided by the Federal Joint Committee (G-BA) with effect from...

more ...

Enhanced speed, contrast, and information: New contrast mechanism improves xenon MRI

Xenon magnetic resonance imaging offers deep insights into the human body and opens up new possibilities in the diagnosis and treatment of diseases.

more ...

A potent weapon against lymphomas

MDC researchers have developed a new approach to CAR T-cell therapy. The team has shown in Nature Communications that the procedure is very effective, especially when it comes to fighting follicular l...

more ...

Events Buch Berlin

14.09.2021, 09:00
GMP Biotech Summer School

Good Manufacturing Practice (GMP) Basic Course Biotechnology (English)

more ...

This website is supported by: